Nanodrugs Targeting Key Factors of Ferroptosis Regulation for Enhanced Treatment of Osteoarthritis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Osteoarthritis (OA) is a widespread degenerative joint disease.
• Ferroptosis, a regulated form of cell death, plays a significant role in OA progression.
• Current OA therapies targeting ferroptosis often focus on single pathways, limiting efficacy.

Purpose of the Study:

• To develop and evaluate a novel multi-target nanoparticle system for OA treatment.
• To investigate the therapeutic potential of Ce@D&P nanoparticles in regulating ferroptosis and mitigating OA.
• To assess the efficacy of Ce@D&P NPs in both in vitro and in vivo OA models.

Main Methods:

• Synthesis and characterization of reactive oxygen species (ROS)-responsive Ce@D&P nanoparticles.
• In vitro evaluation using IL-1β-stimulated chondrocytes to assess ROS levels, inflammation, iron chelation, and extracellular matrix (ECM) metabolism.
• Transcriptomics and metabolomics analyses to elucidate the underlying mechanisms.
• In vivo assessment in a destabilization of the medial meniscus (DMM)-induced mouse model of OA via intra-articular injection.

Main Results:

• Ce@D&P nanoparticles effectively reduced ROS levels, inflammation, and iron-dependent ferroptosis in chondrocytes.
• The nanoparticles balanced chondrocyte ECM metabolism and demonstrated therapeutic effects in vitro.
• Transcriptomics and metabolomics revealed that Ce@D&P NPs regulate oxidative stress and lipid metabolism.
• Intra-articular injection of Ce@D&P NPs in mice alleviated cartilage damage and slowed OA progression.

Conclusions:

• Ce@D&P nanoparticles represent a promising multi-target drug delivery system for OA.
• This novel nanoparticle system effectively targets ferroptosis and offers a potential therapeutic strategy for osteoarthritis treatment.
• The findings suggest Ce@D&P NPs could be an effective approach for managing OA progression.